| Active substance | Tafasitamab |
| Holder | Clinigen Healthcare Ltd on behalf of Incyte Ltd |
| Status | closed |
| Indication | the treatment of adult patients who have Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and who are not eligible for autologous stem cell transplantation (ASCT) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 26/10/2023 |